Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.

"Declarations Ethics approvalAll participating sites received Institutional Review Board or ethics committees approval for the protocol. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Consent to participateAll patients in the MEDALIST study provided written informed consent. Conflict of interestUG has received research support from BMS and Novartis; speaker honorarium from BMS, Jazz Pharmaceuticals, and Novartis; and consulting fees from BMS. PF has received research support and honoraria from BMS. UP has received research funding from Amgen, BMS, Janssen, Merck, and Novartis; consulting fees from BMS; honoraria from AbbVie, BMS, Geron, Janssen, Novartis, and Takeda. RB has received research funding and honoraria for advisory boards from BMS and Taiho Pharma. VS has served on advisory boards for BMS, Geron, Gilead, Menarini, Novartis, and Takeda; and has served on speaker’s bureau for BMS and Novartis. MD-C reports honoraria, consulting fees, and travel support, and has served on advisory boards for BMS, Novartis, and Takeda. AY, DT, GZ, DM, and CH are employees of BMS, and hold stock ownership. SF and XH are employees of BMS. RZ is an employee of GSK and former employee of BMS. RSK reports consulting fees from AbbVie, Acceleron Pharma, BMS, Geron, Jazz Pharmaceuticals, and Novartis; and speakers bureau or honoraria for AbbVie, BMS, CTI BioPharma, Innovent, Jazz Pharmaceuticals, Novartis, PharmaEssentia, Taiho Oncology, and Takeda. AMZ reports consultancy fees from AbbVie, Acceleron, Agios, Amgen, Aprea, Astellas, BeyondSpring, Boehringer-Ingelheim, Cardiff Oncology, Cardinal Health, Celgene/BMS, Daiichi Sankyo, Epizyme, Geron, Gilead, Incyte, Ionis, Janssen, Jazz, Kura, Novartis, Otsuka, Pfizer, Seattle Genetics, Syndax, Taiho, Takeda, Trovagene, and Tyme; research funding for AbbVie, ADC Therapeutics, Amgen, Aprea, Astex, Boehringer-Ingelheim, Cardiff Oncology, BMS, Incyte, Medimmune/Astrazeneca, Novartis, Otsuka, Pfizer, Takeda, and Trovagene; honoraria for AbbVie, Acceleron, Agios, Amgen, Aprea, Astellas, Beyondpspring, Boehringer-Ingelheim, Cardiff Oncology, Cardinal Health, Celgene/BMS, Daiichi Sankyo, Epizyme, Geron, Gilead, Incyte, Ionis, Janssen, Jazz, Kura, Novartis, Otsuka, Pfizer, Seattle Genetics, Syndax, Taiho, Takeda, Trovagene, and Tyme; clinical trial committees for Abbvie, BMS, Geron, Gilead, Kura, and Novartis; and travel support for Cardiff Oncology, Novartis, and Pfizer. GG-M reports grant or research support from AbbVie, Amphivena, Aprea, BMS, Curis, Forty Seven, H3 Biomedicine, Helsinn, Merck, Novartis, and Onconova; and consultancy fees from Astex, BMS, Genentech, and Helsinn. Conflict of interest UG has received research support from BMS and Novartis; speaker honorarium from BMS, Jazz Pharmaceuticals, and Novartis; and consulting fees from BMS. PF has received research support and honoraria from BMS. UP has received research funding from Amgen, BMS, Janssen, Merck, and Novartis; consulting fees from BMS; honoraria from AbbVie, BMS, Geron, Janssen, Novartis, and Takeda. RB has received research funding and honoraria for advisory boards from BMS and Taiho Pharma. VS has served on advisory boards for BMS, Geron, Gilead, Menarini, Novartis, and Takeda; and has served on speaker’s bureau for BMS and Novartis. MD-C reports honoraria, consulting fees, and travel support, and has served on advisory boards for BMS, Novartis, and Takeda. AY, DT, GZ, DM, and CH are employees of BMS, and hold stock ownership. SF and XH are employees of BMS. RZ is an employee of GSK and former employee of BMS. RSK reports consulting fees from AbbVie, Acceleron Pharma, BMS, Geron, Jazz Pharmaceuticals, and Novartis; and speakers bureau or honoraria for AbbVie, BMS, CTI BioPharma, Innovent, Jazz Pharmaceuticals, Novartis, PharmaEssentia, Taiho Oncology, and Takeda. AMZ reports consultancy fees from AbbVie, Acceleron, Agios, Amgen, Aprea, Astellas, BeyondSpring, Boehringer-Ingelheim, Cardiff Oncology, Cardinal Health, Celgene/BMS, Daiichi Sankyo, Epizyme, Geron, Gilead, Incyte, Ionis, Janssen, Jazz, Kura, Novartis, Otsuka, Pfizer, Seattle Genetics, Syndax, Taiho, Takeda, Trovagene, and Tyme; research funding for AbbVie, ADC Therapeutics, Amgen, Aprea, Astex, Boehringer-Ingelheim, Cardiff Oncology, BMS, Incyte, Medimmune/Astrazeneca, Novartis, Otsuka, Pfizer, Takeda, and Trovagene; honoraria for AbbVie, Acceleron, Agios, Amgen, Aprea, Astellas, Beyondpspring, Boehringer-Ingelheim, Cardiff Oncology, Cardinal Health, Celgene/BMS, Daiichi Sankyo, Epizyme, Geron, Gilead, Incyte, Ionis, Janssen, Jazz, Kura, Novartis, Otsuka, Pfizer, Seattle Genetics, Syndax, Taiho, Takeda, Trovagene, and Tyme; clinical trial committees for Abbvie, BMS, Geron, Gilead, Kura, and Novartis; and travel support for Cardiff Oncology, Novartis, and Pfizer. GG-M reports grant or research support from AbbVie, Amphivena, Aprea, BMS, Curis, Forty Seven, H3 Biomedicine, Helsinn, Merck, Novartis, and Onconova; and consultancy fees from Astex, BMS, Genentech, and Helsinn."

"Funding Open Access funding enabled and organized by Projekt DEAL. This study was supported by Celgene, a Bristol Myers Squibb Company, in collaboration with Acceleron Pharma Inc., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA."